Your session is about to expire
← Back to Search
Trabectedin + Immunotherapy for Soft Tissue Sarcoma
Study Summary
This trial is investigating if a combination of drugs can effectively treat NSCLC.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2010 Phase 3 trial • 672 Patients • NCT00113607Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have previously been treated with specific immunotherapy drugs.My kidney function, measured by creatinine levels, is within the normal range.I am not pregnant or breastfeeding.I have received immunotherapy targeting CTLA4 or PD-1.I am not pregnant and agree to use effective birth control during and after the study.I have not had ongoing or uncontrolled diarrhea in the last 4 weeks.I haven't had recent severe gut issues like diverticulitis or blockages in the last 6 months.I have an autoimmune disease like rheumatoid arthritis or lupus.My sarcoma cannot be removed by surgery and has spread.I have a condition affecting my adrenal glands.I am 18 years old or older.My brain metastases are treated, and I've been stable without steroids for 2 weeks.I am fully active and can carry on all my pre-disease activities without restriction.I have a hormone disorder caused by my pituitary gland.I haven't had vaccines for infectious diseases in the last 4 weeks.I have tested positive for HIV/AIDS.My liver function tests are within the required range.I haven't had cancer treatment like radiation or chemotherapy in the last 2 weeks.I have cancer cells in the fluid around my brain and spinal cord.I am on immunosuppressive therapy or I am HIV positive.I have Crohn's disease or ulcerative colitis.I have heart failure or had a recent heart problem.I have (not) been treated before, depending on the study phase I am entering.My blood, kidney, or liver tests are not within the normal range.I understand the study's risks and have signed the consent form.I am willing and able to follow the study's procedures and be available for its duration.My skin condition covers 25% or more of my body.
- Group 1: Phase 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you illustrate the research conducted on Trabectedin to date?
"Currently, there are 779 active studies being conducted on Trabectedin with 88 of them in the third phase. These clinical trials are largely centered around Pittsburgh, Pennsylvania but can be found at 42897 centres worldwide."
How extensive is the current participant pool for this experiment?
"Correct. According to clinicaltrials.gov, the experimental trial commencing on April 13th 2017 is currently recruiting participants and requires 45 people from a single location for completion."
Are there any vacancies available within this research project?
"The data presented on clinicaltrials.gov indicates that this medical experiment is in its active recruitment phase, having initially been posted on April 13th 2017 and most recently updated on May 4th 2022."
What maladies is Trabectedin typically prescribed for?
"Trabectedin is typically used to treat inoperable melanoma, but it can also be prescribed for squamous cell carcinoma and a heightened risk of recurrence."
Share this study with friends
Copy Link
Messenger